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Alternative splicing of survivin mRNA gives rise to multiple isoforms, that is, survivin and 3 splice variants, survivin-2B, survivin-3B and
survivin-DEx3. The aim of this study was to compare the expression of survivin, survivin-2B and survivin-DEx3 in normal breast tissue,
fibroadenomas, primary breast cancer and axillary nodal metastases. Survivin, survivin-2B and survivin-DEx3 mRNA were measured
using semiquantitative RT–PCR. In the primary carcinomas, we related mRNA for each form of survivin to both survivin protein and
apoptosis. For each type of breast tissue, survivin was the predominant form detected, being present in 146 out of 156 (93.6%)
primary breast carcinomas, 11 out of 11 (100%) axillary nodal metastases, 21 out of 31 (67.7%) fibroadenomas and five out of 22
(22.7%) specimens of normal breast tissue. Levels of the three forms of survivin were significantly higher in the carcinomas compared
to normal breast tissue (Po0.0001). Levels of both survivin-2B and survivin-DEx3 but not survivin were significantly higher in nodal
metastases than primary carcinomas. Survivin mRNA levels correlated significantly with survivin protein. Finally, both survivin and
survivin-DEx3 but not survivin-2B correlated positively with apoptosis. Although survivin, survivin-2B and survivin-DEx3 were all
detected in both malignant and nonmalignant breast tissue, the predominant form was survivin. Our results suggest that the different
forms of survivin may have different roles in apoptosis in breast cancer.
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Survivin is a member of the inhibitor of apoptosis (IAP) family of
molecules and is involved in both inhibition of apoptosis and
regulation of cell division. Although rarely expressed in terminally
differentiated normal adult tissues, survivin is upregulated in most
malignancies (Reed, 2001; Altieri, 2003). For example, SAGE
analysis of the expression profile of 3.5 million transcripts in
diverse cancer types identified survivin as one of the top four
transcripts upregulated in malignancy (Velculescu et al, 1999).
These original findings using SAGE analysis have now been
confirmed in multiple cancer types using standard techniques such
as immunohistochemistry and RT–PCR (Altieri, 2003). This
upregulation combined with its dual role in apoptosis and cell
division suggests that survivin plays a critical role in cancer.
In addition to the original survivin transcript described by
Ambrosini et al (1997), three survivin splice variants have been
identified (Mahotka et al, 1999; Badran et al, 2004). Survivin-2B
has an additional exon of 69 base pairs, while survivin-DEx3 lacks
118 base pairs of exon 3 (Mahotka et al, 1999). Survivin-3B, which
was only recently identified, contains five exons including exon 3B
derived from a 165-base pair long portion of intron 3 (Badran et al,
2004). In transfection experiments, survivin-DEx3 demonstrated
similar antiapoptotic potential to survivin but survivin-2B
exhibited reduced antiapoptotic potential (Mahotka et al, 1999).
A possible antiapoptotic role for survivin 3B remains to be
determined. In contrast to full-length survivin, relatively little work
has been performed on expression of the survivin splice variants in
tumour tissues.
The aim of this study was therefore to examine expression of
survivin, survivin-2B and survivin-DEx3 mRNA in a large panel of
primary breast carcinomas, axillary nodal metastases from
primary breast cancers, fibroadenomas and normal breast tissues.
In the primary carcinomas, we related mRNA for the three forms
of survivin to tumour histopathological characteristics, hormone
receptors, survivin protein and levels of apoptosis.
MATERIALS AND METHODS
Sample processing
Breast carcinomas, breast fibroadenomas, normal breast tissue
samples and nodal metastases from breast cancer patients were
obtained at the time of surgery, snap frozen in liquid nitrogen and
stored at  801C. Normal breast tissues were obtained from
reduction mammoplasty tissues (n¼6), normal tissue adjacent to
fibroadenomas (n¼2) and normal tissue adjacent to carcinomas
(n¼14). Although these tissues are referred to as ‘normal’ breast
tissues, it is important to point out that they cannot be regarded as
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s‘healthy normal’ specimens. A detailed description of the primary
breast carcinomas used is shown in Table 1. Tissue samples were
homogenised using a Mikro-Dismembrator U (Braun Biotech Intl.,
Melsungen, Germany) to yield a fine powder. An aliquot of the
powder was extracted with 50mM Tris buffer (pH 7.4) containing
1m M monothioglycerol and assayed for oestrogen receptor (ER)
and progesterone receptor (PR) by ELISA (Abbott Diagnostics, N
Chicago, IL, USA). The cutoff points for ER and PR were
200fmolg
 1 wet weight tissue and 1000fmolg
 1 wet weight tissue,
respectively.
RNA extraction
RNA extractions were performed using an RNace Total Pure kit
(Bioline, Randolph, MA, USA). RNA integrity was assessed by gel
electrophoresis and concentrations were measured spectrophoto-
metrically.
RT–PCR analysis
cDNA was synthesized from 1mg of total RNA, using 50mM oligo
(dT)12–18 primers (Promega, Madison, WI, USA), 0.4mM dNTPs
(Promega), 1  MMLV buffer and 100U of MMLV reverse
transcriptase (Invitrogen Life Technologies, Carlsbad, CA, USA).
PCR was performed using primers which amplify the various
survivin splice variants (forward: 50-GCA TGG GTG CCC CGA
CGT TG-30, reverse: 50-GCT CCG GCC AGA GGC CTC AA-30).
GAPDH was used as an internal control (forward: 50-GCC TCA
AGA TCA TCA GCA A-30, reverse: 50- CCA GCG TCA AAG GTG
GAG-30). Briefly, the 25ml reaction mix contained 1ml cDNA,
250mM dNTPs, 50ng of each primer, Taq polymerase buffer
(10mM Tris-HCl (pH 9.0), 50mM KCl, 0.1% Triton
sX-100 (TBS-
T)) and 1.25U Taq polymerase (Promega). Amplification condi-
tions were as follows: 2min at 941C, followed by 30 cycles of 30s at
94
oC, 1min at 621C and 1min at 721C with a final extension of
5min at 721C. The PCR products were visualised on a 2% agarose
gel. Band intensities for all visible bands were measured by
densitometry using the Eagle Eye gel documentation system
(Stratagene, La Jolla, CA, USA) and expressed as arbitrary units,
relative to GAPDH. The three survivin PCR products were gel
purified using a DNA extraction kit (Qiagen, Valencia, CA, USA)
and sequenced on an ABI Prism 310 instrument to verify the
identity of the bands.
Detection of survivin by Western blotting
Tissue cytosols were diluted in sodium dodecyl sulphate (SDS)
buffer containing 50mM Tris-HCL (pH 6.8), 5% beta mercap-
toethanol, 2% SDS, 8% glycerol and 0.01% bromophenol blue and
heated to 951C for 5min. In all, 200mg of cytosolic protein extract
from each sample was separated on a 15% SDS–polyacrylamide
gel. Recombinant survivin, generously donated by Dr K Shiraki,
Mie University School of Medicine, Mie, Japan, was included in
each experiment as a positive control. Following electrophoresis,
the separated proteins were transferred to a nitrocellulose
membrane (Sigma, St Louis, MO, USA) using a semi-dry blotting
apparatus for 45min. The membranes were then treated for 1h at
room temperature with a blocking solution containing 50mM Tris-
buffered saline (TBS), 5% skimmed milk powder and 0.05%
Triton-X-100 (TBS-T) (Sigma, St Louis, MO, USA). Following this,
the membranes were incubated overnight at 41C with mouse
monoclonal anti-survivin (1:1000) (Novus Biologicals, Littleton,
CO, USA), in a blocking solution containing 50mM TBS-T and 1%
skimmed milk powder. Subsequently, membranes were washed in
50mM TBS containing 0.05% Triton and then probed with
horseradish peroxidase (HRP)-conjugated goat anti-mouse sec-
ondary antibody (Sigma). The blots were washed three times for
10min each in 50mM TBS-T followed by a 10min wash in 50mM
TBS. Immunoreactivity was detected using enhanced chemilumi-
nescence (ECL) reagent (Luminol, Santa Cruz, CA, USA). As a
control for equal loading, membranes were reprobed with mouse
anti-b-actin antibody (Sigma, St Louis, MO, USA). Protein levels
were quantified using densitometry on an Eagle Eye gel
documentation system (Stratagene, La Jolla, CA, USA).
Measurement of apoptosis
Apoptosis was measured by the Cell Death Detection ELISA
(Roche, Mannheim, Germany) as previously described (O’Dono-
van et al, 2003). Briefly, 30mg of cytosolic extract from each sample
was incubated in 96-well microtitre plates coated with biotin-
conjugated anti-histone antibody for 1h. After four washes,
samples were incubated with biotin-conjugated anti-DNA antibody
for 1h at room temperature. ABTS (2,20-azino-bis-(3-benzthiazo-
line-6-sulfonic acid)) solution was used for colorimetric detection.
Absorbances were measured at 405nm and at a reference
wavelength of 490nm. A nucleosome-positive control included in
the kit was used in each assay.
Statistical analysis
Nonparametric Spearman Rank correlations, Mann–Whitney U-
tests and w
2 tests were performed using StatView 5.0.1 (SAS
Institute Inc., Cary, NC, USA). A P-value of o0.05 was regarded as
statistically significant.
RESULTS
Expression of survivin variants in nonmalignant and
malignant breast tissue
Following RT–PCR, three different bands were seen (Figure 1).
Based on sequence analysis, the three bands corresponded to
survivin, survivin-2B and survivin-DEx3. Table 2 summarises the
distribution of the three forms of survivin in normal breast tissue,
fibroadenomas, primary breast carcinomas and axillary nodal
Table 1 Characteristics of primary carcinomas used
Characteristic n %
Size (cm)
p2 34 21.8
42 114 73.1
Unknown 8 5.1
Grade
1+2 57 36.5
3 77 49.4
Unknown 22 14.1
Nodal status
Positive 85 54.5
Negative 63 40.4
Unknown 8 5.1
ER status
Positive 102 65.4
Negative 41 26.3
Unknown 13 8.3
PR status
Positive 56 35.9
Negative 90 57.7
Unknown 10 6.4
Histology
Ductal (D) 115 73.7
Lobular (L) 25 16.0
Mixed D+L 11 7.1
Unknown 5 3.2
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smetastases from primary breast cancers. For each type of breast
tissue investigated, survivin was the predominant form detected.
Survivin was detected in 93.6% (146 out of 156) of primary breast
carcinomas and in all of the 11 axillary nodal metastases
investigated compared to 22.7% (5 out of 22) of normal breast
tissues and 67.7% (21 out of 31) of fibroadenomas. Of the five
normal breast tissues, positive for survivin, three were from tissue
remote from a carcinoma while two were from reduction
mammoplasty specimens. The two splice variants, survivin-2B
and survivin-DEx3, were only detected in one out of 22 (4.5%)
normal breast tissue sample. Levels of the three forms of survivin
were significantly higher in the primary carcinomas than in the
normal breast specimens (Po0.0001 for each form). Levels of
survivin-2B and survivin-DEx3 were significantly higher in the
nodal metastases than in the primary cancers (for survivin-2B,
P¼0.0007; for survivin-DEx3, P¼0.02) (Table 2).
In the primary carcinomas expression of survivin correlated
strongly with survivin-2B and survivin-DEx3 (for survivin-2B,
Po0.0001, r¼0.454; for survivin-DEx3, Po0.0001, r¼0.617). In
addition, expression of the 2B variant correlated with expression of
the DEx3 variant (Po0.0001, r¼0.728). The survivin-2B and
survivin-DEx3 splice variants were not detected in any sample
lacking survivin.
Relationship between survivin and characteristics of the
primary cancers
Table 3 summarises the relationship between survivin, survivin-2B
and survivin-DEx3 and characteristics of the primary cancers. No
significant correlation was found between any of the survivin
forms investigated and tumour grade, ER or PR status. Levels of
survivin-DEx3 showed a weak inverse relationship with tumour
size (r¼ 0.16, P¼0.017, n¼148) and numbers of nodal
metastases (r¼ 0.10, P¼0.042, n¼148). Levels of survivin-
DEx3 were also significantly higher in ductal compared to lobular
cancers (P¼0.0388, n¼140) (Table 3).
Relationship between survivin splice variants and survivin
protein
Survivin protein was measured by Western blotting in 73 primary
carcinomas. The survivin antibody detected a single band of
16.5kDa. Survivin protein was detected in 86.6% (63 out of 73) of
the primary breast carcinomas. Levels of full-length survivin
mRNA correlated with survivin protein (r¼0.48, P¼0.041,
n¼73). Of the 73 cancers, both survivin mRNA and protein were
detected in 64 (87.7%) and was negative for both in two (2.7%) of
the samples. Seven (9.6%) were positive at the mRNA level but
negative at the protein level. Survivin protein was not found in any
sample lacking detectable survivin mRNA. Survivin protein did
not correlate with the levels of either survivin-2B or survivin-DEx3
(for survivin-2B, r¼0.21, P¼0.324; for survivin-DEx3, r¼0.19,
P¼0.259).
Relationship between survivin variants and apoptosis in
primary carcinomas
Survivin has been shown to inhibit apoptosis but the relationship
between the survivin splice variants and apoptosis has not
previously been investigated in breast cancer. Levels of apoptosis
Survivin-2B 
Survivin 
Survivin-∆Ex3
GAPDH 
Figure 1 RT–PCR products of survivin, survivin-2B and survivin-DEx3 in
eight representative primary breast carcinoma samples. The identity of each
band was confirmed by sequencing.
Table 2 Frequency and median levels of survivin, survivin-2B and survivin-DEx3 mRNA in normal breast tissue, fibroadenomas, primary breast cancer and
axillary nodal metastases from breast cancer
Survivin Survivin-2B Survivin-DEx3
Tissue No. positive (%) Median level No. positive (%) Median level No. positive (%) Median level
Normal breast (n¼22) 5 (22.7) 0 1 (4.5) 0 1 (4.5) 0
Fibroadenoma (n¼31) 21 (67.7) 0.118 15 (48.4) 0 16 (51.6) 0
Primary breast carcinoma (n¼156) 146 (93.6) 0.467 96 (61.5) 0.041 86 (55.1) 0.025
Nodal metastases (n¼11) 11 (100) 0.509 9 (81.8) 0.255 5 (45.5) 0.197
Table 3 Relationship between survivin, survivin-2B and survivin-DEx3
and established prognostic factors in breast cancer
Median levels (OD units/relative to GAPDH)
Characteristic n Survivin Survivin-2B Survivin-DEx3
Size (cm)
p2 34 0.488 0.096 0.134
42 114 0.523 0.110 0.142
Nodal status
Positive 85 0.490 0.113 0.118
Negative 63 0.534 0.103 0.157
Histology
Ductal(D) 115 0.549 0.112 0.146*
Lobular (L) 25 0.386 0.075 0.084
Mixed D+L 11 0.405 0.114 0.159
Grade
1+2 57 0.495 0.104 0.133
3 77 0.568 0.124 0.154
ER status
Positive 102 0.508 0.108 0.146
Negative 41 0.519 0.111 0.146
PR status
Positive 56 0.503 0.089 0.143
Negative 90 0.525 0.125 0.154
*Denotes a P-value of o0.05.
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swere measured in 65 of the primary carcinoma samples using the
Cell Death Detection ELISA, which measures nucleosomes released
during DNA fragmentation. As shown in Figures 2A and B, levels
of both survivin and survivin-DEx3 mRNA showed a moderate
positive correlation with apoptosis (for survivin, r¼0.38,
P¼0.012; for survivin-DEx3, r¼0.37, P¼0.023). In contrast, no
significant correlation was found between survivin-2B and
apoptosis (n¼65, r¼0.28, P¼0.121).
DISCUSSION
Although expression of survivin has been widely studied in cancer
(Altieri, 2003; Li, 2003), there are relatively few reports on its splice
variants. Indeed to our knowledge, only one previous study has
investigated survivin splice variants in breast cancer. In 2003,
O’Driscoll et al reported that survivin, survivin-DEx3 and survivin-
2B were present in 68, 55 and 9.4% of breast cancers, respectively.
Compared to O’Driscoll et al (2003), we found that all of the three
forms were detected in a higher proportion of carcinomas. This
difference was particularly marked for survivin-2B and may relate
to the fact that different PCR procedures were used in the two
studies. Although the same survivin primers were used in both
studies, there were differences in the protocol. In particular, the
use of an abundant transcript, b-actin, as an endogenous PCR
control may explain differences in the sensitivity of detection of
less-abundant transcripts such as the survivin splice variants.
Similar to previous studies in both gastric (Krieg et al, 2002) and
renal carcinomas (Mahotka et al, 2002a) as well as breast cancer
(O’Driscoll et al, 2003), we show here that full-length survivin is
also the main form of survivin expressed in normal breast tissue,
fibroadenomas and breast carcinomas.
Survivin, survivin-2B and survivin-DEx3 mRNAs were detected
at significantly lower frequencies and lower levels in the normal
breast tissue compared to the primary breast carcinomas. Levels of
the two splice variants but not full-length survivin were
significantly higher in nodal metastases compared to the primary
breast cancers.
Although early studies showed little or no expression of survivin
in normal differentiated tissues (Adida et al, 1998; Altieri 2003; Li
2003), we found that survivin was detected in five out of 22
samples of normal breast tissue and 21 out of 31 fibroadenomas.
The splice variants however, were detected in only one of the 22
normal breast tissues tested, that is, in a sample remote from a
carcinoma. Consistent with our data, Hirohashi et al (2002) failed
to detect the splice variants in a number of normal adult tissues.
These findings suggest that survivin-2B and survivin-DEx3 may be
more specific markers for malignancy than survivin itself.
Although survivin mRNA levels were significantly higher in
primary breast cancer compared to fibroadenomas, survivin was
detected in greater than half of the fibroadenomas investigated,
which suggests that survivin may play a role in the development of
these benign tumours.
In agreement with previous studies (Tanaka et al, 2000; Nasu
et al, 2002; Kennedy et al, 2003), we found no significant
correlation between survivin and tumour size, tumour grade,
nodal status, histology type or hormone receptor status. However,
a weak but significant inverse relation was found between
survivin-DEx3 and both tumour size and number of nodal
metastases. This form of survivin was also detected more
frequently in ductal compared to lobular primary carcinomas.
Previously, we reported that caspase 3 levels were also significantly
higher in ductal than lobular breast cancers (O’Donovan et al,
2003). These findings suggest that the regulation of apoptosis is
different in ductal and lobular breast cancers.
Although the number of nodal metastases investigated in this
study was relatively small, that is, 11, all samples were positive for
survivin. If this preliminary result can be confirmed with larger
numbers of samples, survivin could be a sensitive marker for
detecting micrometastases in lymph nodes from breast cancer
patients. In this context, it should be pointed out that in
melanoma, patients with survivin-positive sentinel lymph nodes
had a significantly worse outcome than those with survivin-
negative nodes (Gradilone et al, 2002).
Survivin protein correlated significantly with survivin mRNA in
the 73 primary carcinomas tested. The antibody used for Western
blotting was a monoclonal antibody raised against full-length
recombinant survivin protein and can be blocked using a survivin
C-terminus peptide (amino acids 129–142). Omission of exon 3 in
survivin-DEx3 causes a frame-shift in exon 4, which results in an
altered C-terminus in the predicted survivin-DEx3 protein. There-
fore, the antibody used would not be expected to detect survivin-
DEx3 protein. Survivin-2B includes amino acids 129–142 of survivin
and the predicted molecular weight of the survivin-2B protein is
18.6kDa. However, we did not observe any bands of 18.6kDa. A
single band of 16.5kDa, which is the expected size for survivin
protein, was observed in all samples positive for survivin protein.
In this study, we showed that levels of both survivin and
survivin-DEx3 but not survivin-2B correlated significantly with
apoptosis. As mentioned in the introduction, Mahotka et al (1999)
reported that survivin and survivin-DEx3 were antiapoptotic,
whereas survivin-2B exhibited a reduced antiapoptotic ability.
Indeed, it has been suggested that that the 2B variant might be a
naturally occurring antagonist of survivin and survivin-DEx3,
possibly by competitive binding to a common interaction partner
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Figure 2 Relationship between both survivin mRNA (A) and survivin-
DEx3 mRNA (B) and apoptosis levels in primary breast cancer. OD units
are optical density units.
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s(Mahotka et al, 1999, 2002b). Why survivin and survivin-DEx3
correlate positively with apoptosis is unclear. A possible explana-
tion, however, is that upregulation of survivin expression occurs in
response to the increased caspase levels and/or rates of apoptosis,
which is found in breast cancer (Krajewski et al, 1999; Mommers
et al, 1999; Zhao et al, 2002; O’Donovan et al, 2003). It should be
pointed out that Sarela et al (2002), in a study on pancreatic
cancer, also found a significant and positive correlation between
survivin mRNA and apoptosis. In other reports, however, either an
inverse relationship (Kawasaki et al, 2001; Satoh et al, 2001) or no
significant relationship has been found between survivin and rates
of apoptosis in tumours (Beardsmore et al, 2003).
While this work was in progress, a new variant of survivin, that
is, survivin-3B was described (Badran et al, 2004). Survivin-3B
comprises five exons, including a novel exon 3B of 165 base pairs
derived from intron 3. As survivin-3B contains a BIR domain, it is
likely to participate in apoptosis. The survivin primers used in this
study should detect survivin-3B as a PCR product 165 base
pairs larger than survivin. A band of that size was however,
not observed using conventional gel electrophoresis. This may
mean that it is not expressed in breast tissue or that our assay may
not be sensitive enough to detect it. The presence or absence of this
splice variant in breast tissue could be confirmed by PCR with
specific primers for the 3B variant as described by Badran et al
(2004).
Clearly, further work is necessary to establish the biological role
for the different forms of survivin. In order to address a potential
clinical value for the three forms of survivin investigated in this
study, we will, in the future, relate each survivin form to both
patient outcome and response to therapy.
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